Ken Griffin Harmony Biosciences Holdings, Inc. Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$28.81 - $33.01 $164,217 - $188,157	-5,700 Reduced 72.15%	2,200 $66,000
Q1 2024 May 15, 2024	SELL	$29.93 - $35.06 $442,964 - $518,888	-14,800 Reduced 65.2%	7,900 $265,000
Q4 2023 Feb 14, 2024	BUY	$19.2 - $33.78 $360,960 - $635,064	18,800 Added 482.05%	22,700 $733,000
Q3 2023 Nov 14, 2023	SELL	$31.89 - $39.03 $95,670 - $117,090	-3,000 Reduced 43.48%	3,900 $127,000
Q2 2023 Aug 14, 2023	SELL	$30.5 - $37.4 $518,500 - $635,800	-17,000 Reduced 71.13%	6,900 $242,000
Q1 2023 May 15, 2023	BUY	$30.8 - $53.92 $689,920 - $1.21 Million	22,400 Added 1493.33%	23,900 $780,000
Q4 2022 Feb 14, 2023	SELL	$45.4 - $60.91 $3.82 Million - $5.12 Million	-84,100 Reduced 98.25%	1,500 $82,000
Q3 2022 Nov 14, 2022	BUY	$42.06 - $55.45 $2.19 Million - $2.88 Million	52,000 Added 154.76%	85,600 $3.79 Million

228

45.4M

48.2K

61.5K

Ticker HRMY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,161,400
Market Cap $2.31B
Description
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.